%	O
%	O
TITLE	O

Human	O
papillomavirus	O
infection	O
in	O
head	O
and	O
neck	O
cancer	O
:	O
the	O
role	O
of	O
the	O
secretory	O
leukocyte	O
protease	O
inhibitor	O
.	O

%	O
%	O
ABSTRACT	O

We	O
previously	O
showed	O
that	O
secretory	O
leukocyte	O
protease	O
inhibitor	O
(	O
SLPI	O
)	O
gene	O
and	O
protein	O
expression	O
is	O
significantly	O
lower	O
in	O
metastatic	O
versus	O
non	O
-	O
metastatic	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
.	O

However	O
,	O
we	O
did	O
not	O
assess	O
the	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
status	O
of	O
these	O
cases	O
.	O

Since	O
SLPI	O
plays	O
a	O
role	O
in	O
HIV	O
and	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
infections	O
,	O
we	O
hypothesized	O
that	O
SLPI	O
may	O
be	O
involved	O
in	O
HPV	O
-	O
infected	O
HNSCC	O
.	O

In	O
HNSCC	B-Study_Cohort
tissue	I-Study_Cohort
(	I-Study_Cohort
n=54	I-Study_Cohort
)	I-Study_Cohort
,	O
HPV	O
DNA	O
was	O
determined	O
and	O
correlated	O
with	O
SLPI	O
expression	O
.	O

Additionally	O
,	O
to	O
investigate	O
a	O
possible	O
role	O
of	O
smoking	O
on	O
SLPI	O
expression	O
in	O
clinically	O
normal	O
mucosa	O
,	O
19	O
patients	O
treated	O
for	O
nonâ€‘malignant	O
diseases	O
(	O
non	O
-	O
HNSCC	O
)	O
were	O
analyzed	O
for	O
SLPI	O
expression	O
and	O
correlated	O
with	O
smoking	O
habits	O
.	O

In	O
HNSCC	O
patients	O
,	O
SLPI	O
expression	O
showed	O
a	O
significant	O
inverse	O
correlation	O
with	O
HPV	O
status	O
.	O

In	O
patients	O
with	O
moderate	O
/	O
strong	O
SLPI	O
expression	O
(	O
n=19	O
)	O
,	O
10	O
.	O
5	O
%	O
were	O
HPV	O
-	O
positive	O
.	O

By	O
contrast	O
,	O
patients	O
with	O
absent	O
/	O
weak	O
SLPI	O
expression	O
(	O
n=35	O
)	O
,	O
45	O
.	O
7	O
%	O
were	O
HPV	O
-	O
positive	O
.	O

Low	O
SLPI	O
expression	O
was	O
correlated	O
with	O
metastasis	O
(	O
P=0	O
.	O
003	O
)	O
independent	O
of	O
HPV	O
status	O
.	O

HPV	O
-	O
positivity	O
was	O
clearly	O
associated	O
with	O
lymph	O
node	O
status	O
(	O
81	O
.	O
3	O
%	O
N1	O
-	O
3	O
cases	O
)	O
.	O

In	O
smoking	O
non	O
-	O
HNSCC	O
patients	O
(	O
n=7	O
)	O
,	O
42	O
.	O
9	O
%	O
showed	O
absent	O
/	O
weak	O
and	O
57	O
.	O
1	O
%	O
moderate	O
/	O
strong	O
SLPI	O
staining	O
.	O

In	O
non	O
-	O
smoking	O
non	O
-	O
HNSCC	O
patients	O
(	O
n=10	O
)	O
83	O
.	O
3	O
%	O
showed	O
absent	O
/	O
weak	O
and	O
16	O
.	O
7	O
%	O
moderate	O
/	O
strong	O
SLPI	O
expression	O
.	O

For	O
the	O
first	O
time	O
,	O
a	O
correlation	O
between	O
SLPI	O
downregulation	O
and	O
HPV	O
infection	O
was	O
demonstrated	O
,	O
suggesting	O
that	O
high	O
levels	O
of	O
SLPI	O
,	O
possibly	O
induced	O
by	O
environmental	O
factors	O
such	O
as	O
tobacco	O
smoking	O
,	O
correlate	O
with	O
protective	O
effects	O
against	O
HPV	O
infection	O
.	O

SLPI	O
may	O
be	O
a	O
potential	O
biomarker	O
identifying	O
head	O
and	O
neck	O
cancer	O
patients	O
not	O
at	O
risk	O
of	O
developing	O
metastases	O
(	O
SLPI	O
-	O
positive	O
)	O
,	O
and	O
those	O
at	O
risk	O
to	O
be	O
infected	O
by	O
HPV	O
(	O
SLPI	O
-	O
negative	O
)	O
and	O
likely	O
to	O
develop	O
metastases	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Patients	O
,	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
,	I-HPV_Sample_Type
DNA	O
and	O
RNA	O
extraction	O
.	O

From	O
2004	B-Study_Time
to	I-Study_Time
2009	I-Study_Time
,	O
tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
of	O
histopathologically	B-Study_Cohort
confirmed	I-Study_Cohort
HNSCC	I-Study_Cohort
were	I-Study_Cohort
obtained	I-Study_Cohort
from	I-Study_Cohort
54	I-Study_Cohort
patients	I-Study_Cohort
(	O
42	O
male	O
and	O
12	O
female	O
;	O
range	O
,	O
43	B-Minimum_Age_in_Study_Cohort
-	O
76	B-Maximum_Age_in_Study_Cohort
years	O
;	O
median	O
,	O
58	O
years	O
)	O
during	O
surgery	O
at	O
the	O
Department	O
of	O
Otorhinolaryngology	O
,	O
Head	O
and	O
Neck	O
Surgery	O
at	O
the	O
Christian	O
-	O
Albrechts	O
-	O
University	O
Kiel	O
,	O
Germany	B-Study_Location
.	O

All	O
samples	B-HPV_Sample_Type
were	O
obtained	O
following	O
informed	O
consent	O
approved	O
by	O
the	O
local	O
Ethics	O
Committee	O
(	O
D	O
438	O
/	O
10	O
)	O
.	O

Tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
were	O
treated	O
as	O
follows	O
:	O
one	O
section	O
of	O
the	O
tumor	O
tissue	B-HPV_Sample_Type
was	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
and	O
stored	O
at	O
-	O
80˚C	O
for	O
further	O
analysis	O
.	O

The	O
remaining	O
section	O
of	O
each	O
tumor	O
was	O
processed	O
for	O
routine	O
histopathology	O
.	O

DNA	O
was	O
extracted	O
from	O
25	O
mg	O
frozen	O
tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
,	O
as	O
previously	O
described	O
(	O
20	O
,	O
19	O
)	O
.	O

Total	O
RNA	O
was	O
extracted	O
using	O
peqGOLD	O
TriFast	O
reagent	O
(	O
PeqLab	O
,	O
Erlangen	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
anatomical	O
location	O
of	O
the	O
primary	O
tumors	O
was	O
:	O
tonsils	O
[	O
(	O
n=20	O
)	O
;	O
palatine	O
tonsil	O
(	O
n=14	O
)	O
,	O
lingual	O
tonsil	O
(	O
n=6	O
)	O
]	O
,	O
larynx	O
(	O
n=22	O
)	O
,	O
tongue	O
(	O
n=8	O
)	O
,	O
and	O
soft	O
palate	O
(	O
n=4	O
)	O
.	O

SCC	O
of	O
the	O
tongue	O
(	O
anatomical	O
localization	O
of	O
the	O
oral	O
cavity	O
)	O
and	O
SCC	O
of	O
the	O
soft	O
palate	O
(	O
per	O
definition	O
anatomical	O
localization	O
of	O
the	O
oropharynx	O
)	O
were	O
investigated	O
in	O
one	O
subgroup	O
(	O
n=12	O
)	O
since	O
the	O
biological	O
behavior	O
of	O
soft	O
palate	O
SCC	O
is	O
more	O
compa	O
-	O
rable	O
to	O
oral	O
cavity	O
SCC	O
than	O
to	O
tonsillar	O
SCC	O
(	O
per	O
definition	O
anatomical	O
localization	O
of	O
the	O
oropharynx	O
)	O
.	O

Additional	O
clini	O
-	O
copathological	O
characteristics	O
and	O
tobacco	O
smoking	O
habits	O
are	O

presented	O
in	O
Table	O
I	O
.	O

We	O
also	O
obtained	O
tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
from	O
clinically	O
normal	O
mucosa	O
of	O
the	O
aerodigestive	O
tract	O
from	O
19	O
patients	O
(	O
12	O
male	O
and	O
7	O
female	O
;	O
range	O
,	O
2	B-Minimum_Age_in_Study_Cohort
-	O
63	B-Maximum_Age_in_Study_Cohort
years	O
;	O
median	O
,	O
43	O
years	O
)	O
who	O
were	O
treated	O
for	O
non	O
-	O
malignant	O
diseases	O
at	O
our	O
Department	O
.	O

Additional	O
clinicopathological	O
characteristics	O
and	O
tobacco	O
smoking	O
habits	O
are	O
presented	O
in	O
Table	O
II	O
.	O

Detection	O
of	O
HPV	O
DNA	O
.	O

Two	O
different	O
PCR	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
based	I-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
methods	I-HPV_Lab_Technique
for	O
HPV	O
DNA	O
were	O
applied	O
to	O
increase	O
precision	O
in	O
validity	O
and	O
reliability	O
of	O
HPV	O
DNA	O
diagnostics	O
:	O
multiplex	O
HPV	O
genotyping	O
(	O
MPG	O
)	O
assay	O
and	O
HPVType	O
3	O
.	O
5	O
LCD	O
-	O
Array	O
,	O
as	O
previously	O
described	O
(	O
20	O
-	O
22	O
;	O
Table	O
I	O
)	O
.	O

Detection	O
of	O
HPV	O
E6	O
*	O
I	O
mRNA	O
in	O
fresh	O
frozen	O
tissue	B-HPV_Sample_Type
.	O

In	O
cases	O
with	O
RNA	O
available	O
for	O
analysis	O
(	O
n=37	O
)	O
,	O
total	O
RNA	O
was	O
subjected	O
to	O
ultra	O
-	O
short	O
type	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
specific	I-HPV_Lab_Technique
RT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
assays	O
which	O
were	O
developed	O
for	O
12	O
HR	O
-	O
and	O
8	O
pHR	O
-	O
HPV	O
to	O
amplify	O

~	O
65	O
bp	O
of	O
the	O
E6	O
*	O
I	O
mRNA	O
(	O
23	O
)	O
.	O

RNA	O
integrity	O
was	O
assessed	O
by	O
co	O
-	O
amplification	O
of	O
81	O
bp	O
of	O
ubiquitin	O
C	O
transcripts	O
.	O

PCR	B-HPV_Lab_Technique
products	O
were	O
detected	O
by	O
Luminex	O
hybridization	O
.	O

The	O
cut	O
-	O
off	O
value	O
(	O
5	O
net	O
MFI	O
)	O
to	O
define	O
HPV	O
E6	O
*	O
I	O
mRNA	O
-	O
positivity	O
was	O
applied	O
as	O
previously	O
described	O
(	O
23	O
)	O
.	O

Immunohistochemistry	B-HPV_Lab_Technique
for	I-HPV_Lab_Technique
SLPI	I-HPV_Lab_Technique
.	O

Paraffin	O
-	O
embedded	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
were	O
cut	O
into	O
5	O
-	O
µm	O
sections	O
,	O
and	O
stained	O
for	O
SLPI	O
expression	O
as	O
previously	O
described	O
(	O
1	O
)	O
.	O

The	O
slides	O
were	O
reviewed	O
by	O
two	O
experienced	O
members	O
of	O
the	O
Department	O
of	O
Otorhinolaryngology	O
,	O
Head	O
and	O
Neck	O
Surgery	O
,	O
Kiel	O
,	O
and	O
by	O
an	O
experienced	O
pathologist	O
.	O

To	O
assess	O
SLPI	O
protein	O
levels	O
,	O
300	O
cells	O
in	O
at	O
least	O
five	O
areas	O
were	O
analyzed	O
.	O

The	O
mean	O
percentage	O
of	O
positive	O
tumor	O
cells	O
was	O
determined	O
and	O
cases	O
were	O
assigned	O
to	O
one	O
of	O
the	O
following	O
categories	O
:	O
(	O
-	O
)	O
<	O
5	O
%	O
;	O
(	O
+	O
)	O
5	O
-	O
30	O
%	O
;	O
(	O
+	O
+	O
)	O
31	O
-	O
75	O
%	O
;	O
and	O
(	O
+	O
+	O
+	O
)	O
>	O
75	O
%	O
.	O

Cases	O
with	O
a	O
score	O
of	O
(	O
-	O
)	O
were	O
considered	O
negative	O
,	O
cases	O
with	O
scores	O
of	O
(	O
+	O
,	O
+	O
+	O
,	O
+	O
+	O
+	O
)	O
positive	O
.	O

Algorithm	O
for	O
defining	O
HPV	O
-	O
positivity	O
.	O

In	O
the	O
present	O
study	O
,	O
specimens	B-HPV_Sample_Type
were	O
classified	O
as	O
HPV	O
DNA	O
-	O
positive	O
only	O
if	O
the	O
HPV	O
DNA	O
was	O
detected	O
by	O
the	O
HPVType	O
3	O
.	O
5	O
LCD	O
-	O
Array	O
and	O
/	O
or	O
in	O
the	O
presence	O
of	O
high	O
viral	O
loads	O
by	O
BSGP5	B-HPV_Lab_Technique
+	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
6	I-HPV_Lab_Technique
+	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
MPG	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
.	O

HPV	O
infections	O
were	O
classified	O
as	O
active	O
if	O
HPV	O
E6	O
*	O
I	O
mRNA	O
was	O
detected	O
.	O

When	O
RNA	O
was	O
not	O
available	O
,	O
HPV	O
DNA	O
-	O
positive	O
cases	O
with	O
p16INK4A	O
overexpression	O
were	O
clas	O
-	O
sified	O
as	O
active	O
.	O

Statistical	O
analyses	O
.	O

Fisher	O
'	O
s	O
exact	O
test	O
was	O
performed	O
to	O
test	O
for	O
differences	O
between	O
groups	O
,	O
using	O
the	O
SAS	O
9	O
.	O
2	O
software	O
.	O

All	O
tests	O
were	O
performed	O
two	O
-	O
sided	O
,	O
and	O
P	O
-	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
to	O
indicate	O
statistically	O
significant	O
differences	O
.	O

